Group 1 - The actual controller of Haohai Biological Technology, Jiang Wei, was penalized approximately 19.34 million yuan for insider trading and suggesting others to trade securities, with 4.71 million yuan confiscated as illegal gains and a fine of 14.63 million yuan imposed by the China Securities Regulatory Commission [2][4]. - Haohai Biological Technology stated that the penalty is directed at Jiang Wei personally and is unrelated to the company, asserting that it will not significantly impact the company's daily operations, business, or finances [4][5]. - As of the end of the third quarter, Jiang Wei is the largest shareholder of Haohai Biological Technology, holding 66.528 million shares, which accounts for 28.6% of the total shares [4][5]. Group 2 - Haohai Biological Technology plans to enter the biological amniotic membrane sector by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan [7]. - Ruiji Biological specializes in the research, production, and sales of biological amniotic membranes, which are used in orthopedic and ophthalmic fields [7]. - The investment aims to enhance Haohai's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [7]. Group 3 - Ruiji Biological's financial performance is concerning, with a projected net profit of -12.74 million yuan for 2024 and a loss of 11.93 million yuan for the first three quarters of 2025 [8][9]. - The transaction does not include performance commitments or profit guarantees, indicating potential risks for Haohai if Ruiji's performance declines [9]. - As of December 23, Haohai Biological Technology's stock price was 44.25 yuan per share, with a total market capitalization of 10.292 billion yuan [10].

Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, has been penalized approximately 19.34 million yuan for insider trading and related activities, which includes the confiscation of illegal gains and fines imposed by the China Securities Regulatory Commission [1][2]. Group 1: Penalty Details - Jiang Wei was fined 1.463 million yuan and had illegal gains of 471 million yuan confiscated by the China Securities Regulatory Commission [1][2]. - The penalty is directed at Jiang Wei personally and is stated to have no significant impact on the company's daily operations or financial status [4]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei holds 66.528 million shares, representing 28.6% of Haohai Biological Technology's total shares [4]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [5]. Group 3: Business Developments - Haohai Biological Technology plans to invest 38.3515 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [6]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [6]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.7415 million yuan for 2024, with a loss of 11.9327 million yuan in the first nine months of 2025 [7][8]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological Technology if Ruiji's performance declines [8].